Attitudes of patients with schizophrenia toward placebo-controlled clinical trials

Journal of Clinical Psychiatry

Volumn 64, Issue 3, 2003, Pages 277-281

  Hummer, Martina ^a   Holzmeister, Roswitha ^b   Kemmler, Georg ^b   Eder, Ursula ^b   Hofer, Alex ^b   Kurzthaler, Ilsemarie ^b   Oehl, Maria ^b   Weiss, Elisabeth ^b   Fleischhacker, W Wolfgang ^b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO;

ADULT; ANXIETY DISORDER; ARTICLE; ASTHENIA; CLINICAL TRIAL; DECISION MAKING; DEPRESSION; DISEASE SEVERITY; DOCTOR PATIENT RELATION; FEMALE; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICAL ETHICS; MEMORY DISORDER; MENTAL CONCENTRATION; MENTAL DISEASE; NEGATIVE SYNDROME; PATIENT ATTITUDE; POSITIVE SYNDROME; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SEDATION; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STATISTICAL ANALYSIS; WEIGHT GAIN;

EID: 0037365511     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0308     Document Type: Article

References (28)

1. Storosum JG, Elferink AJA, van Zwieten BJ. Schizophrenia: do we really need placebo-controlled studies'? Eur Neuropsychopharmacol 1998;8:279-286
2. Rothman KJ, Michels KB. The continuing unethical use of placebo-controls. N Engl J Med 1994;331:394-398
3. Streiner DL. Placebo-controlled trials: when are they needed? Schizophr Res 1999;15:201-210
4. Miller FG. Placebo-controlled trials in psychiatric research: an ethical perspective. Biol Psychiatry 2000;47:707-716
5. Singer P. Placebo-controlled studies in schizophrenia: ethical and scientific perspectives. Schizophr Res 1999;35:227-236
6. Weijer C. Placebo-controlled trials in schizophrenia: are they ethical? are they necessary? Schizophr Res 1999;35:211-218
7. Carpenter WT, Schooler NR, Kane JM. The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry 1997;54:401-407
8. Volavka J. Are medication-free periods necessary for phase 3 trials of new antipsychotic medications? Arch Gen Psychiatry 1998;55:280-281
9. World Medical Association Declaration of Helsinki. Edinburgh, Scotland: 52nd WMA General Assembly; October 2000
10. Johnson DA, Pasterski G, Ludlow JM, et al. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 1983;67:339-352
11. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995;52:173-188
12. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-897
13. Curson DA, Hirsch SR, Platt SD, et al. Does short term placebo treatment of chronic schizophrenia produce long term harm? BMJ 1986;293:726-728
14. Lasagna L. Decision processes in establishing the efficacy and safety of psychotropic agents. In: Prien RF, Robinson DS, eds. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. New York, NY: Raven Press; 1994:13-28
15. Levine RJ. The need to revise the Declaration of Helsinki. N Engl J Med 1999;341:531-534
16. Weltgesundheitsorganisation. Internationale Klassifikation psychischer Störungen. ICD-10. Bern: Verlag Hans Huber; 1993
17. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
18. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;(suppl 334):1-100
19. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-183
20. Roberts LW. The ethical basis of psychiatric research: conceptual issues and empirical findings. Compr Psychiatry 1998;39:99-110
21. Hall LL. Medication discontinuation and symptom provocation in research: a consumer and family perspective. Biol Psychiatry 1999;46:1017-1020
22. Appelbaum P, Lidz C, Meisel A. Informed Consent: Legal Theory and Clinical Practise. Oxford, England: Oxford University Press; 1987
23. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report. Washington, DC: Dept of Health, Education and Welfare; 1978
24. President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Summing Up. Washington, DC: Government Printing Office; 1983
25. Grisso T, Appelbaum PS. The MacArthur Treatment Competence Study, III: abilities of patients to consent to psychiatric and medical treatments. Law Human Behav 1995;19:149-174
26. Mattocks KM, Horwitz RI. Placebos, active control groups, and the unpredictable paradox. Biol Psychiatry 2000;47:693-698
27. Mohr P, Czobor P. Subject selection for the placebo- and comparator-controlled trials of neuroleptics in schizophrenia. J Clin Psychopharmacol 2000;20:240-254
28. Fleischhacker WW, Volavka J, Hummer M, et al. Placebo-controlled trials in patients suffering from schizophrenia: feasibility, ethical and methodological considerations. Schizophrenia Res 2001;49(suppl):227-228